XML 30 R18.htm IDEA: XBRL DOCUMENT v3.21.1
SEGMENTED INFORMATION
3 Months Ended
Mar. 31, 2021
SEGMENTED INFORMATION  
NOTE 12 - SEGMENTED INFORMATION

At March 31, 2021, the Company (“BGLC”) operates in biochemical industry segment through its two Malaysian subsidiaries, BioNexus Malaysia and Chemrex.  

 

The corporate structure as at March 31, 2021 is depicted below:

 

 

 

BioNexus Gene Lab Corp.,

a Wyoming company

 

 

 

 

 

 

 

 

 

 

 

 

 

 

100% owned

 

 

 

100% owned

Bionexus Gene Lab Sdn. Bhd.,

a Malaysian company

 

 

 

Chemrex Corporation Sdn. Bhd.,

a Malaysian Company

               

For the quarter ended March 31, 2021, segmented (unaudited) revenue and net profit/(loss) (Currency expressed in United States Dollars (“US$”) are as follows:

 

 

 

BioNexus Malaysia

 

 

Chemrex

 

 

Total

 

 

Consolidated with BGLC

 

 

 

Three months ended March 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REVENUE

 

$ 97,363

 

 

$ 3,351,796

 

 

$ 3,449,159

 

 

$ 3,449,159

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(67,707 )

 

 

(2,798,887 )

 

 

(2,866,594 )

 

 

(2,866,594 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

29,656

 

 

 

552,909

 

 

 

582,565

 

 

 

582,565

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

763

 

 

 

61,625

 

 

 

62,388

 

 

 

62,388

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

(22,511 )

 

 

(233,152 )

 

 

(255,663 )

 

 

(302,851 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(1,207 )

 

 

(2,151 )

 

 

(3,358 )

 

 

(3,358 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PROFIT BEFORE TAX

 

 

6,701

 

 

 

379,231

 

 

 

385,932

 

 

 

338,744

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense:

 

 

0

 

 

 

0

 

 

 

0

 

 

 

0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET PROFIT

 

$ 6,701

 

 

$ 379,231

 

 

$ 385,932

 

 

$ 338,744

 

 

 

 

BioNexus Malaysia

 

 

Chemrex

 

 

Total

 

 

Consolidated with BGLC

 

 

 

Three months ended March 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REVENUE

 

$ 0

 

 

$ 3,070,026

 

 

$ 3,070,026

 

 

$ 3,070,026

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(12,992 )

 

 

(2,401,727 )

 

 

(2,414,719 )

 

 

(2,414,719 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS (LOSS)/PROFIT

 

 

(12,992 )

 

 

668,299

 

 

 

655,307

 

 

 

655,307

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

4,745

 

 

 

741,896

 

 

 

746,641

 

 

 

746,641

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

(20,149 )

 

 

(290,635 )

 

 

(310,784 )

 

 

(328,418 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(1,063 )

 

 

(1,963 )

 

 

(3,026 )

 

 

(3,026 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(LOSS)/PROFIT BEFORE TAX

 

 

(29,459 )

 

 

1,117,597

 

 

 

1,088,138

 

 

 

1,070,504

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense:

 

 

(860 )

 

 

0

 

 

 

(860 )

 

 

(860 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET (LOSS)/PROFIT

 

$ (30,319 )

 

$ 1,117,597

 

 

$ 1,087,278

 

 

$ 1,069,644

 

  

 

 

As Of March 31, 2021 and December 31, 2020

 

 

 

Total Assets

 

 

Total Liabilities

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bionexus (M)

 

$ 816,893

 

 

$ 902,552

 

 

$ 711,549

 

 

$ 800,610

 

Chemrex

 

 

8,894,730

 

 

 

9,008,245

 

 

 

2,976,336

 

 

 

3,283,814

 

TOTAL

 

 

9,711,623

 

 

 

9,910,797

 

 

 

3,687,885

 

 

 

4,084,424